- Home
- HUYA vs RGNX Comparison
HUYA vs RGNX Comparison
Compare HUYA & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUYA
- RGNX
- Stock Information
- Founded
- HUYA 2014
- RGNX 2008
- Country
- HUYA China
- RGNX United States
- Employees
- HUYA N/A
- RGNX N/A
- Industry
- HUYA Computer Software: Programming Data Processing
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HUYA Technology
- RGNX Health Care
- Exchange
- HUYA Nasdaq
- RGNX Nasdaq
- Market Cap
- HUYA 713.8M
- RGNX 661.2M
- IPO Year
- HUYA 2018
- RGNX 2015
- Fundamental
- Price
- HUYA $2.68
- RGNX $11.61
- Analyst Decision
- HUYA Strong Buy
- RGNX Strong Buy
- Analyst Count
- HUYA 2
- RGNX 7
- Target Price
- HUYA $4.25
- RGNX $30.29
- AVG Volume (30 Days)
- HUYA 936.8K
- RGNX 533.2K
- Earning Date
- HUYA 11-12-2025
- RGNX 11-06-2025
- Dividend Yield
- HUYA 92.74%
- RGNX N/A
- EPS Growth
- HUYA N/A
- RGNX N/A
- EPS
- HUYA N/A
- RGNX N/A
- Revenue
- HUYA $852,782,043.00
- RGNX $161,318,000.00
- Revenue This Year
- HUYA $8.16
- RGNX $198.02
- Revenue Next Year
- HUYA $5.11
- RGNX $2.67
- P/E Ratio
- HUYA N/A
- RGNX N/A
- Revenue Growth
- HUYA N/A
- RGNX 91.30
- 52 Week Low
- HUYA $2.21
- RGNX $5.04
- 52 Week High
- HUYA $4.59
- RGNX $13.93
- Technical
- Relative Strength Index (RSI)
- HUYA 36.64
- RGNX 50.12
- Support Level
- HUYA $2.65
- RGNX $10.80
- Resistance Level
- HUYA $2.93
- RGNX $12.05
- Average True Range (ATR)
- HUYA 0.11
- RGNX 0.68
- MACD
- HUYA 0.01
- RGNX -0.17
- Stochastic Oscillator
- HUYA 22.86
- RGNX 29.76
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.